Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies-Reference-Cited by-同舟云学术

Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies

Published:2012-04-30 Issue:7 Volume:103 Page:1290-1295
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Ogura Michinori¹,Tsukasaki Kunihiro²,Nagai Hirokazu³,Uchida Toshiki¹,Oyama Takashi¹,Suzuki Tatsuya¹,Taguchi Jun²,Maruyama Dai⁴,Hotta Tomomitsu⁵,Tobinai Kensei⁴

Affiliation:

1. Department of Hematology and Oncology; Nagoya Daini Red Cross Hospital; Nagoya; Japan

2. Department of Hematology; Atomic Bomb Disease Institute; Nagasaki University Graduate School of Biomedical Science; Nagasaki; Japan

3. Clinical Research Center; National Hospital Organization Nagoya Medical Center; Nagoya; Japan

4. Department of Hematology and Hematopoietic Stem Cell Transplantation; National Cancer Center Hospital; Tokyo; Japan

5. National Hospital Organization Nagoya Medical Center; Nagoya; Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2012.02287.x/fullpdf

Reference15 articles.

1. Purine nucleoside phosphorylase deficiency;Markert;Immunodefic Rev,1991

2. Forodesine: review of preclinical and clinical data;Al-Kali;Future Oncol,2010

3. Response to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a phase I/II study (Abstract);Duvic;Blood,2007

4. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;J Clin Oncol,1999

5. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma;Olsen;J Clin Oncol,2007

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives and challenges in developing small molecules targeting purine nucleoside phosphorylase;European Journal of Medicinal Chemistry;2024-05

2. Forodesine maintenance therapy for newly diagnosed peripheral T-cell lymphoma: a single-institutional, observational, retrospective analysis;Annals of Hematology;2022-06-25

3. SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP;Cell Reports;2020-05

4. Development of new agents for peripheral T-cell lymphoma;Expert Opinion on Biological Therapy;2019-01-29

5. Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma;Annals of Hematology;2018-07-05